Archive for the ‘Diabetic Retinopathy’ Category

Diabetic Retinopathy - What an Ophthamologist Sees

Diabetic retinopathy is one of the leading causes of blindness in the United States. For diabetics, it is the leading cause. Diabetic retinopathy is the result of microvascular retinal changes in the eye. New veins and capillaries begin to grow. However, these new growths aren’t healthy, and often bleed, which causes the customary vision-blurring and eye reddening. Here are the top 5 tips for preventing diabetic retinopathy.

1. Know the symptoms – Double vision, flashing lights, redness or blood in the eye, difficulty reading…all of these are symptoms of diabetic retinopathy. Be sure to schedule an optometrist appointment if you experience any of these. Early diagnosis is key to keeping your vision.
2. Regular eye exams – as soon as you are diagnosed with diabetes, be sure to make an appointment with your ophthalmologist. You may have been living with the disease for some time, raising your risk of diabetic retinopathy. After this, be sure to get regular eye exams. Your ophthalmologist will be able to catch any retinopathy before it becomes serious. We recommend annual exams for diabetics.
3. Maintain your blood sugar – if your blood glucose levels rapidly rise, it can actually change the shape of your eye’s lens. This can cause blurred vision.
4. Exercise – overall wellness is important not just for your eyes, but to keep your diabetes in check. It also helps to maintain your blood pressure. High blood pressure can cause a cloudy lens and blurred vision. Be sure to talk to your doctor about the right exercise regimen for your body.
5. Protect your eyes – eye protection is important for everyone, not just diabetics. Remember to wear protective sunglasses when at the beach, on the water, and especially on the ski slopes. White snow’s reflective quality can cause eye damage.

SOUTHAMPTON, England, August 23, 2011 /PRNewswire

KalVista Pharmaceuticals (“KalVista”), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised £8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and a major unmet medical need. KalVista’s advanced pre-clinical product pipeline is targeting both intravitreal injection and oral administration routes. KalVista acquired these inhibitors plus all relevant intellectual property from Vantia Therapeutics.

KalVista’s scientific founders include world-leading experts in ophthalmology, diabetes and diabetes-related complications, Dr Lloyd Paul Aiello and Dr Edward P. Feener. Dr Aiello is Professor of Ophthalmology at Harvard Medical School, Director of the Joslin’s Beetham Eye Institute and Inaugural Chair of the National Eye Institute Diabetic Retinopathy Clinical Research Network.

Read the full article

Eye vessels

ScienceDaily (2010-01-08) — Scientists have discovered a link between diabetes and bone marrow nerve damage that may help treat one of the most common and potentially blindness-causing diabetes complications – diabetic retinopathy.

The key to better treating retinopathy – damage to blood vessels in the retina that affects up to 80 percent of diabetic patients – lies not in the retina but in damage to the nerves found in bone marrow that leads to the abnormal release of stem cells, said Julia Busik, an associate professor in MSU’s Department of Physiology.

> read full article